Update shared on20 Aug 2025
Fair value Decreased 7.14%The consensus price target for BioGaia has been revised down to SEK130.00, primarily reflecting a decline in the company’s expected future P/E ratio.
What's in the News
- BioGaia launched a subsidiary, BioGaia New Sciences AB, to develop microbiome-friendly products beyond gut, immune, and oral health, focusing first on skin health.
- The skin microbiome market is entering a rapid growth phase, projected to reach USD 2.86 billion by 2032 (CAGR 13.7%).
- Maik Lepatey, with significant experience in skin care and beauty, has been appointed CEO of BioGaia New Sciences, supported by an expert team in dermatology and product development.
- BioGaia New Sciences has launched BioGaia Aldermis, a probiotic ointment for infants and children with dry and sensitive skin, currently available in North America, and acquired new microbiome-friendly skincare formulations.
- BioGaia AB has scheduled a Special/Extraordinary Shareholders Meeting in Stockholm.
Valuation Changes
Summary of Valuation Changes for BioGaia
- The Consensus Analyst Price Target has fallen from SEK140.00 to SEK130.00.
- The Future P/E for BioGaia has fallen from 28.58x to 26.98x.
- The Net Profit Margin for BioGaia remained effectively unchanged, moving only marginally from 28.58% to 28.17%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.